JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tan, K-B
Right arrow Articles by Putti, T C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tan, K-B
Right arrow Articles by Putti, T C
Journal of Clinical Pathology 2005;58:535-538
© 2005 BMJ Publishing Group Ltd & Association of Clinical Pathologists


ORIGINAL ARTICLE

Cyclooxygenase 2 expression in nasopharyngeal carcinoma: immunohistochemical findings and potential implications

K-B Tan1, T C Putti2

1 Department of Pathology, National University of Singapore, Lower Kent Ridge Road, Singapore 119074
2 Department of Pathology, National University of Singapore

Correspondence to:
Dr K-B Tan
Department of Pathology, National University of Singapore, Lower Kent Ridge Road, Singapore 119074; pattankb{at}nus.edu.sg Background: Cyclooxygenase 2 (COX-2), an inducible prostaglandin synthase, participates in inflammatory and neoplastic processes. It is expressed by various tumours and contributes to carcinogenesis. Notably, COX-2 inhibitors appear to have tumour suppressor effects and are being evaluated in clinical trials.

Aims: To investigate COX-2 expression in nasopharyngeal carcinoma (NPC), a common tumour in parts of Asia, and to discuss potential implications.

Methods: Eighty five cases of NPC were reviewed. COX-2 immunohistochemistry and semiquantitative assessment of expression in nasopharyngeal biopsies were performed. Because COX-2 is proangiogenic, tumour microvessel density was also assessed with the use of CD31 immunohistochemistry.

Results: Histologically, 78 NPCs were undifferentiated, six were non-keratinising, and one was keratinising. Thirty nine NPCs had adjacent dysplastic epithelium. COX-2 expression was noted in 60 NPCs, 14 of 39 samples of dysplastic epithelium, and only one of 25 samples of normal epithelium (p < 0.01). Microvessel density was not significantly different between COX-2 positive and COX-2 negative tumours (p = 0.774). Tumour COX-2 positivity was not associated with higher tumour stage (p = 0.423).

Conclusion: COX-2 expression is more frequently seen as nasopharyngeal epithelium progresses from normal to dysplastic to carcinoma. This suggests that COX-2 contributes to the multistep process of NPC carcinogenesis. COX-2 represents a therapeutic target for COX-2 inhibitors, and there is thus a basis for the further investigation of this adjuvant treatment modality for NPC. COX-2 inhibitors are known to potentiate the antitumour effects of radiotherapy, which is the primary treatment for NPC.


Abbreviations: COX, cyclooxygenase; EBV, Epstein-Barr virus; MVD, microvessel density; NPC, nasopharyngeal carcinoma

Keywords: nasopharyngeal carcinoma; cyclooxygenase; head and neck; undifferentiated carcinoma; upper aerodigestive tract




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
D. Chatterjee, E. Sabo, R. Tavares, and M. B. Resnick
Inverse Association between Raf Kinase Inhibitory Protein and Signal Transducers and Activators of Transcription 3 Expression in Gastric Adenocarcinoma Patients: Implications for Clinical Outcome
Clin. Cancer Res., May 15, 2008; 14(10): 2994 - 3001.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
R. Soo, J Wu, A Aggarwal, Q Tao, W Hsieh, T Putti, K. Tan, W. Soon, Y. Lai, B Mow, et al.
Celecoxib reduces microvessel density in patients treated with nasopharyngeal carcinoma and induces changes in gene expression
Ann. Onc., November 1, 2006; 17(11): 1625 - 1630.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2005 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.